New antiviral agents for the treatment of hepatitis C: ABT-450.

Abstract

INTRODUCTION:

Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88 - 100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging.

AREAS COVERED:

Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented.

EXPERT OPINION:

Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.

• Authors: Andres F Carrion, Julio Gutierrez, Paul Martin
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 15 Issue 5 Pg. 711-6 (Apr 2014) ISSN: 1744-7666 [Electronic] England
• PMID: 24517400 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• Cyclopropanes
• Lactams, Macrocyclic
• Macrocyclic Compounds
• NS3 protein, hepatitis C virus
• Sulfonamides
• Viral Nonstructural Proteins
• Ribavirin
• Proline
• Ritonavir
• paritaprevir

Topics

• Antiviral Agents (therapeutic use)
• Cyclopropanes
• Drug Therapy, Combination
• Genotype
• Hepacivirus (drug effects, genetics)
• Hepatitis C (drug therapy)
• Hepatitis C, Chronic (drug therapy)
• Humans
• Lactams, Macrocyclic
• Macrocyclic Compounds (therapeutic use)
• Proline (analogs & derivatives)
• Ribavirin (therapeutic use)
• Ritonavir (therapeutic use)
• Sulfonamides
• Viral Nonstructural Proteins (antagonists & inhibitors)